Reducing agalsidase beta infusion time in Fabry patients: low incidence of antibody formation and infusion-associated reactions in an Italian multicenter study

Table 3 Anti-drug antibodies and infusion-associated reactions during treatment with agalsidase beta

#	Sex	Prior therapy	Genotype	Phenotype	Weight(Kg)	Anti-drug antibodies (titer)^a
						Baseline	1st mo	2nd mo	3rd mo	4th mo	5th mo	6st mo	12th mo
1	M	naïve	p.I354K	Classic	69	0
2	M	naïve	p.P265L	Classic	74	0
3	F	alfa	p.A156V	Classic	48	0
4	M	naïve	c.1213 delA	Classic	60	0					POS3200		POS6400
5	F	naïve	c.1213 delA	Classic	56	0		IARs
6	M	naïve	c.1213 delA	Classic	45	0			POS3200	POS800			POS800
7	F	naïve	c.1213 delA	Classic	58	0
8	F	naïve	c.1213 delA	Classic	67	0
9	F	naïve	p.L414Cfs*3	Classic	58	0
10	M	alfa	p.N215S	Late-onset	83	0	POS3200	POS1600	NEG	NEG			NEG
11	F	naïve	p.S235C	Classic	64	0
12	F	naïve	c.583insG	Classic	55	0
13	M	naïve	c.388 A > G	Classic	70	0
14	M	naïve	c.1284_1287delA	Classic	73	0
15	F	alfa	p.L275H	Classic	48	0
16	F	naïve	p.F113L	Late-onset	67	0
17	F	naïve	p.F113L	Late-onset	66	0
18	M	naïve	p.F113L	Late-onset	65	0
19	F	naïve	p.F113L	Late-onset	52	0
20	F	naïve	p.F113L	Late-onset	64	0
21	M	alfa	p.F273S	Classic	65	0
21	F	alfa	p.R301P	Classic	51	0
23	F	alfa	p.G260E	Classic	79	0						POS200	NEG
24	M	naïve	c.1234 A > C	Classic	57	0
25	M	naïve	IVS5 + 1G > T	Classic	59	0			POS6400	POS3200	POS1600	POS1600	NEG
26	M	naïve	c.1234 A > C	Classic	60	0
27	M	naïve	c.1234 A > C	Classic	60	0
28	F	naïve	c.1234 A > C	Classic	59	0
29	M	naïve	p.I303F	Late-onset	83	0						POS800	POS800
30	F	naïve	p.G85D	Classic	55	0
31	M	naïve	p.N215S	Late-onset	92	0

^a The reportable range of antibody titer was 100 to 204,800
alfa agalsidase alfa, F female, IARs infusion-associated reactions, M male, mo month, NEG negative, POS positive Titer

ISSN: 1750-1172